Clinical trial finds diabetes pill reduces liver scarring

A recent clinical trial has revealed promising results for dapagliflozin, a medication commonly prescribed for type 2 diabetes. Researchers discovered that this SGLT-2 inhibitor significantly alleviated liver inflammation and scarring in patients suffering from non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease. This condition often leads to liver fibrosis, which can progress to cirrhosis and liver failure if left untreated. The study involved a diverse group of participants with varying degrees of liver damage. Over the course of the trial, patients treated with dapagliflozin showed marked improvement in liver health compared to those who received a placebo. The researchers noted a reduction in liver enzymes and fibrosis markers, suggesting that the drug not only slows down liver damage but may also promote healing of the existing scar tissue. These findings could lead to significant advancements in treating liver diseases, offering hope to millions affected by NASH worldwide. As the prevalence of obesity and type 2 diabetes continues to rise, the potential dual benefits of dapagliflozin could position it as a pivotal treatment option. Further studies are needed to confirm these results, but the initial data provides a compelling case for expanding the use of this medication beyond diabetes management.

— Authored by Next24 Live